320 related articles for article (PubMed ID: 32887983)
21. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P; Tiong KLA; Neo JE; Mohan BP; Wijarnpreecha K; Tam YCS; Coppola N; Preda CM; Wong YJ
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515176
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.
Xie J; Xu B; Wei L; Huang C; Liu W
Infect Dis Ther; 2022 Aug; 11(4):1661-1682. PubMed ID: 35749010
[TBL] [Abstract][Full Text] [Related]
23. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
25. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Garcia-Cehic D; Rando A; Rodriguez-Frias F; Gregori J; Costa JG; Carrión JA; Macenlle R; Pamplona J; Castro-Iglesias A; Cañizares A; Tabernero D; Campos C; Buti M; Esteban JI; Quer J
J Viral Hepat; 2021 Sep; 28(9):1319-1324. PubMed ID: 33720484
[TBL] [Abstract][Full Text] [Related]
26. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
27. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
El-Kassas M; Emadeldeen M; Hassany M; Esmat G; Gomaa AA; El-Raey F; Congly SE; Liu H; Lee SS
J Hepatol; 2023 Aug; 79(2):314-320. PubMed ID: 37088312
[TBL] [Abstract][Full Text] [Related]
28. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Gheorghe L; Preda C; Trifan A; Manuc M; Stanciu C; Istratescu D; Popescu CP; Diculescu MM; Tieranu CG; Manuc T; Stroie TG; Iacob SM; Iliescu L
J Gastrointestin Liver Dis; 2022 Dec; 31(4):437-443. PubMed ID: 36535062
[TBL] [Abstract][Full Text] [Related]
29. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
[TBL] [Abstract][Full Text] [Related]
30. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Younossi ZM; Stepanova M; Jacobson IM; Asselah T; Gane EJ; Lawitz E; Foster GR; Roberts SK; Thompson AJ; Willems BE; Welzel TM; Pearlman B; Younossi I; Racila A; Henry L
Aliment Pharmacol Ther; 2018 Jan; 47(2):259-267. PubMed ID: 29181842
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
33. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Papaluca T; Sinclair M; Gow P; Pianko S; Sievert W; Arachchi N; Cameron K; Bowden S; O'Keefe J; Doyle J; Stoove M; Hellard M; Iser D; Thompson A
Liver Int; 2019 Dec; 39(12):2285-2290. PubMed ID: 31355968
[TBL] [Abstract][Full Text] [Related]
34. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
35. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Liu CH; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
J Formos Med Assoc; 2020 Dec; 119(12):1871-1875. PubMed ID: 32553687
[TBL] [Abstract][Full Text] [Related]
36. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
38. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
39. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
[No Abstract] [Full Text] [Related]
40. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Liu CH; Chen CY; Su WW; Liu CJ; Lo CC; Huang KJ; Chen JJ; Tseng KC; Chang CY; Peng CY; Shih YL; Huang CS; Kao WY; Yang SS; Tsai MC; Wu JH; Chen PY; Su PY; Hwang JJ; Fang YJ; Lee PL; Tseng CW; Lee FJ; Lai HC; Hsieh TY; Chang CC; Chang CH; Huang YJ; Kao JH
Clin Mol Hepatol; 2021 Oct; 27(4):575-588. PubMed ID: 34255961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
